Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01696435 · ClinicalTrials.gov registry record · NA
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 18,353
- Enrollment target
NCT01696435 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 18,353 participants.
The verdict
NCT01696435, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 18,353 participants
- Enrollment target
Study Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or fish oil: 1) reduces risk of clinical depressive syndrome, 2) yields better mood scores over time, compared to placebo.
Interventions
- DIETARY_SUPPLEMENT vitamin D3
- DIETARY_SUPPLEMENT Fish oil placebo
- DRUG omega-3 fatty acids (fish oil)
- DIETARY_SUPPLEMENT Vitamin D placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,353 participants |
| Start Date | 2010-07 |
| Est. Completion | 2025-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01696435
The ClinicalTrials.gov registry entry for NCT01696435 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18,353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which vitamin D3 is the first listed.
NCT01696435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01696435 about?
NCT01696435 is a clinical study titled "VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL". The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart dis...
What is the current status of trial NCT01696435?
This trial is currently completed. It is a NA study. The enrollment target is 18,353 participants. The study started on 2010-07. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT01696435?
The interventions under investigation include: vitamin D3 (DIETARY_SUPPLEMENT), Fish oil placebo (DIETARY_SUPPLEMENT), omega-3 fatty acids (fish oil) (DRUG), Vitamin D placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01696435?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.